CEPI (Coalition for Epidemic Preparedness Innovations)
Paul Kristiansen is an accomplished professional in the field of laboratory research and innovations, currently serving as the Director of Laboratory Research & Innovations and Head of Standards and Assays at CEPI since March 2019. With extensive experience at Folkehelseinstituttet from January 2000 to April 2019, Paul held various leadership roles, including Department Director for Bacteriology and Biopharmaceutical Production, along with significant project management responsibilities in vaccine research. Prior experience includes contributions as an instructor for the Norwegian Armed Forces and as a laboratory technician at Nycomed Pharma. Paul holds a Ph.D. in Microbiology from Universitetet i Oslo and an MSc in Biotechnology from Institut national des Sciences appliquées de Toulouse, along with additional studies at Handelshøyskolen BI.
This person is not in the org chart
This person is not in any teams
CEPI (Coalition for Epidemic Preparedness Innovations)
2 followers
CEPI is an innovative partnership between public, private, philanthropic, and civil organisations, launched at Davos in 2017, to develop vaccines against future epidemics. Prior to COVID-19, CEPI’s work focused on developing vaccines against the Ebola Virus Disease, Lassa virus, Middle East Respiratory Syndrome coronavirus, Nipah virus, Rift Valley Fever virus and Chikungunya virus. It has over 20 vaccine candidates against these pathogens in development. CEPI has also invested in new platform technologies for rapid vaccine development against unknown pathogens (Disease X). During the COVID-19 pandemic, CEPI initiated multiple programmes to develop vaccines against SARS-CoV-2 and its variants with a focus on speed, scale, and access. These programmes leverage the rapid response platforms developed by CEPI’s partners prior to the emergence of COVID-19, as well as new collaborations. The aim is to advance clinical development of a diverse portfolio of safe and effective COVID-19 candidates and to enable fair allocation of these vaccines worldwide through COVAX. CEPI’s 5-year plan lays out a $3.5 billion roadmap to compress vaccine development timelines to 100 days, develop a broadly protective vaccine against COVID-19 and other Betacoronaviruses, and create a “library” of vaccine candidates for use against known and unknown pathogens. The plan is available at www.endpandemics.cepi.net